Healios K.K. (HLOSF)

Market Cap	293.91M
Revenue (ttm)	3.93M
Net Income (ttm)	-29.20M
Shares Out	n/a
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	2,895
Open	3.170
Previous Close	2.250
Day's Range	3.170 - 3.170
52-Week Range	0.926 - 3.170
Beta	1.35
RSI	61.97
Earnings Date	Aug 13, 2025

About Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company develops HLCM051, which is preparing for phase 3 clinical trial, as well as preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is in phase 2/3 and phase 3 clinical trial to treat ischemic stroke; and HLCM051, which is in phase 2 clinical trial to treat trauma. It also develops HLCR011, which is in phase 1/2 clinical trial f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLOSF

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.

Financial numbers in JPY